OG真人官方

1.YL Liu, X Wang, N Krishnan, T HSiao, YC Ji, K kenako, MG Teneche, PD Adams, E Zuniga, SM Kaech, LF Zhang and GS Feng. Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded nanoparticles.Hepatology,Accepted, 2025.

2.WS Chen, Y Liang, M Zong, JJ Liu, K Kaneko, KL Hanley, K Zhang, andGS Feng. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.Cell Reports,2021 Vol. 37 Issue 6 Pages 109974

3.Liang, Y, K Kaneko, B Xin, J Lee, X Sun, K Zhang, andGS Feng. Temporal analysis of postnatal liver development and maturation by single cell transcriptomics.Developmental Cell.57, 398-414, 2022

4.K Kaneko, Y Liang, Q Liu, S Zhang, A Scheiter, D Song, andGS Feng. Identification of CD133+ intercellsomes in intercellular communication to offset intracellular signal deficit.eLife.12, Epub on Oct 17, 2023. Accession Number: 37846866, DOI: 10.7554/eLife.86824

5.Bard-Chapeau EA, S Li, J Ding, SS Zhang, HH Zhu, F Princen, DD Fang, T Han, B Bailly-Maitre, V Poli, NM Varki, H Wang andGS Feng.PTPN11/Shp2acts as a tumor suppressor in hepatocellular carcinogenesis.Cancer Cell19, 629-639, 2011.

6.Feng GS, CC Hui, and T Pawson. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases.Science259, 1607-11, 1993.